New drug namilumab tested for lung sarcoidosis – but trial halted early

NCT ID NCT05314517

Terminated Disease control Sponsor: Kinevant Sciences GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for rescue treatments like steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: namilumab
What this could lead to: If successful, namilumab could offer a new treatment option for chronic pulmonary sarcoidosis, potentially reducing the need for steroids.
What could go wrong: The trial was terminated early, so results are limited. It is a Phase 2 study, meaning it is still early and may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOIDOSIS, PULMONARY

Contacts and locations

Locations

Kinevant Study Site

Birmingham, Alabama, 35233, United States
Kinevant Study Site

Palo Alto, California, 94304, United States
Kinevant Study Site

Valencia, California, 91355, United States
Kinevant Study Site

Denver, Colorado, 80206, United States
Kinevant Study Site

Gainesville, Florida, 32610, United States
Kinevant Study Site

Augusta, Georgia, 29841, United States
Kinevant Study Site

Chicago, Illinois, 60612, United States
Kinevant Study Site

Iowa City, Iowa, 52242, United States
Kinevant Study Site

Kansas City, Kansas, 66160, United States
Kinevant Study Site

New Orleans, Louisiana, 70115, United States
Kinevant Study Site

Baltimore, Maryland, 21234, United States
Kinevant Study Site

Minneapolis, Minnesota, 55414, United States
Kinevant Study Site

Rochester, Minnesota, 55905, United States
Kinevant Study Site

Greenville, North Carolina, 27834, United States
Kinevant Study Site

Cincinnati, Ohio, 45219, United States
Kinevant Study Site

Cleveland, Ohio, 44195, United States
Kinevant Study Site

Philadelphia, Pennsylvania, 19140, United States
Kinevant Study Site

Pittsburgh, Pennsylvania, 15213, United States
Kinevant Study Site

Charleston, South Carolina, 29425, United States
Kinevant Study Site

Rock Hill, South Carolina, 29732, United States
Kinevant Study Site

Dallas, Texas, 75390, United States
Kinevant Study Site

Houston, Texas, 77030, United States
Kinevant Study Site

Charlottesville, Virginia, 22908, United States
Kinevant Study Site

Falls Church, Virginia, 22042, United States
Kinevant Study Site

Brussels, 1200, Belgium
Kinevant Study Site

Leuven, 3000, Belgium
Kinevant Study Site

Liège, B-4000, Belgium
Kinevant Study Site

Yvoir, 5530, Belgium
Kinevant Study Site

Bobigny, 93000, France
Kinevant Study Site

Lille, 59037, France
Kinevant Study Site

Paris, 75018, France
Kinevant Study Site

Berlin, 14165, Germany
Kinevant Study Site

Essen, 45239, Germany
Kinevant Study Site

Freiburg im Breisgau, 79106, Germany
Kinevant Study Site

Hanover, 30625, Germany
Kinevant Study Site

Heidelberg, 69126, Germany
Kinevant Study Site

Leiden, 2333 ZA, Netherlands
Kinevant Study Site

Nieuwegein, 3435 CM, Netherlands
Kinevant Study Site

Rotterdam, 3015 GD, Netherlands
Kinevant Study Site

Ankara, 06620, Turkey (Türkiye)
Kinevant Study Site

Istanbul, 34134, Turkey (Türkiye)
Kinevant Study Site

Izmir, 35100, Turkey (Türkiye)
Kinevant Study Site

Izmir, 35330, Turkey (Türkiye)
Kinevant Study Site

Mersin, 33110, Turkey (Türkiye)
Kinevant Study Site

Cambridge, CB20QQ, United Kingdom
Kinevant Study Site

Cottingham, HU165JQ, United Kingdom
Kinevant Study Site

London, SE59RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.